Click and hear Paul G. Richardson present the data for the combination therapy with elotuzumab in combination pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. Elotuzumab, an immunostimulatory monoclonal antibody targeting SLAMF7, enables selective killing of MM cells through multiple mechanisms of action and synergizes with the immunomodulatory drug pomalidomide. This study demonstrated sustained and clinically relevant PFS ...

Despite recent advances in MM therapy, the disease remains incurable. Patients with late-stage RRMM refractory to pomalidomide and/or daratumumab have limited effective treatment options. Melflufen is a novel peptide-conjugated alkylator potentiated by intracellular aminopeptidases, which are markedly overexpressed in multiple myeloma. In this MEDtalk Paul G. Richardson present updated efficacy and safety of melflufen + ...

The SAM domain and HD domain 1 (SAMHD1) protein is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, which has been initially described to restrict human immunodeficiency virus type 1 (HIV-1) in the immune cells. This study shows that SAMHD1 is expressed in approximately half of de novo diffuse large B-cell Lymphomas at a variable level and correlates with cell of origin (GC), biomarkers ...

In this MEDtalk Stine Mikkelsen present the first study investigating submicroscopic copy number variations/ uniparental disomy in idiopathic cytopenia of undetermined significance patients. In a subset of patients with otherwise no detectable genetic abnormalities, Stine Mikkelsen and colleagues identified structural variations involving genes recurrently affected in MDS. Their results suggest that SNP-A can aid the prognostics of ICUS patients by identifying submicroscopic structural variations as risk markers for poor ...

TOURMALINE-MM3 is a phase 3, double-blind, placebo-controlled study, where ixazomibimproved PFS, and is the first study to evaluate the impact ofmaintenance therapyon quality of life in postautologous stem cell transplant in newly diagnosed multiple myeloma. In this MEDtalk Fredrik Schjesvold present the data from the study showing, that active treatment with ixazomibdid not have an ...

The Nordic Myeloma Study Group (NMSG) initiated the CARFI trial, an open randomized phase II study, to investigate the efficacy and safety of carfilzomib as part of induction and conditioning in salvage ASCT and to evaluate the role of carfilzomib/dexamethasone maintenance after salvage ASCT. In this MEDtalk Henrik Gregersen report that maintenance therapy with carfilzomib and dexamethasone maintenance prolongs ...

In this MEDtalk Sigbjørn Berentsen present data that advise EPO use to stimulate bone marrow compensatory response. The results from this international studyshows, that EPO is effective in about 70% of AIHA patients unresponsive to ongoing/previous ...

The rate of bone marrow minimal residual diseaseinduced byibrutinibin combination with fludarabine, cyclophosphamide, rituximabisthe highest ever reported for a regimen treating a population of CLL patients unrestricted by prognostic marker status.  The safety profile of the combination therapy was generally favorable, with typical toxicities of ibrutinib and fludarabine, cyclophosphamideand rituximabobserved, and no additional toxicities discernable with ...

The DALIAH trial is an ongoing investigator initiated Danish multicenter randomized controlled phase III clinical trial. This study shows, that at 36 months the clinicohematologicalORR was higher in patients withessential thrombocythemia, polycythemia veraand prefibroticmyelofibrosistreatedwith hydroxyurea. Click and hear Trine Alma Knudsen explain the new ...

In this MEDtalk The Phase III ASCEND study of the Bruton’s Tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed or refractory CLL are presented for the first time at EHA. In this study, acalabrutinib monotherapy significantly improved PFS with a more tolerable safety profile, compared with idelalisib/ bendamustine in patients with relapsed or refractory CLL, reducing ...

#Siste magasin

FASTLEGER

Nr. 1 • desember 2019
1. Årgang
  • Venøs tromboembolisme ved kreft
  • Type 2-diabetes
  • Hepatitt E-virus